Pharmalot's Ed Silverman says the Food and Drug Administration's new, slower pace for drug approvals is probably the "new normal" for the regulatory body.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.